CJC-1295 Reconstitution Calculator

No. CJC-1295 is an investigational GHRH analog, not FDA-approved for anti-aging, physique, recovery, or routine endocrine use (review/human clinical context). Human studies in healthy adults showed clear GH and IGF-1 stimulation, but commercial development did not lead to approval, and reviews classify it as unapproved and commonly discussed in gray-market practice.

CJC-1295 stimulates pituitary GHRH receptors, increasing endogenous growth hormone release and downstream IGF-1 production (human trial/mechanistic). Its DAC modification covalently associates with albumin, extending activity from hours to roughly a week, unlike native GHRH fragments with very short half-lives. In healthy adults, a single dose increased GH for at least 6 days and IGF-1 for about 9–11 days while preserving pulsatile GH secretion rather than flattening it completely.

Published human studies used single subcutaneous doses of 60–90 mcg/kg, with overnight pulse-analysis data reported after 60 and 90 mcg/kg; higher tested doses did not clearly outperform lower doses for GH pulse parameters in that study (human trial). For a 73 kg/160 lb person, 30–60 mcg/kg corresponds to about 2.2–4.4 mg per injection; 60–90 mcg/kg corresponds to about 4.4–6.6 mg.

Practical use differs from the trials: common community protocols use 1–2 mg subcutaneously once or twice weekly for DAC CJC-1295, or lower nightly dosing with non-DAC “mod GRF 1-29” products (community protocol). Evidence for those community regimens is weaker than the formal human PK/PD studies.

Yes. The human trials and preclinical work used subcutaneous administration, which is the standard route for achieving prolonged albumin-bound exposure and sustained GH/IGF-1 effects (human trial/animal). Oral use is not supported; peptides generally have poor oral bioavailability, and CJC-1295’s studied pharmacology is based on injection. Intramuscular use is occasionally reported in practice, but there is no advantage shown in the corpus over subcutaneous injection (practitioner consensus).

With DAC CJC-1295, clinically relevant endocrine effects last days, not hours (human trial). In healthy adults, GH elevation persisted for at least 6 days and IGF-1 remained elevated for 9–11 days after a single dose. Reviews summarize the effective half-life/activity window as about 6–8 days to roughly 1 week due to albumin binding. This long duration is the key difference from short-acting sermorelin/GHRH fragments.

Human studies mainly evaluated single-dose or short-term endocrine responses, not long-term continuous use for months to years (human trial/review). Because long-term safety data are limited, extended cycles used in practice are empirical rather than evidence-based. Common practice is 8–16 weeks followed by reassessment of IGF-1, fasting glucose, edema, sleep quality, and subjective benefit (community protocol). If IGF-1 rises above range or side effects accumulate, dose reduction or discontinuation is standard (practitioner consensus).

Most concern comes from GH-axis amplification rather than acute toxicity (human trial/review). Reviews note possible edema, water retention, paresthesias/carpal-tunnel-type symptoms, headache, increased appetite, and worsening insulin sensitivity as class effects of GH secretagogues and sustained IGF-1 elevation. Long-term theoretical risks include glucose dysregulation and possible promotion of existing neoplasia through GH/IGF-1 biology, but these risks are not well quantified for CJC-1295 specifically in long-duration human use. Evidence for severe toxicity in short controlled studies is limited, but absence of long-term surveillance is a major gap.

CJC-1295 is a long-acting GHRH analog; ipamorelin is a ghrelin-receptor agonist (GHS-R1a), sermorelin is a shorter-acting GHRH analog, and tesamorelin is a more clinically developed GHRH analog with approved use in HIV-associated visceral adiposity (review). Compared with sermorelin, CJC-1295 lasts far longer because of DAC-mediated albumin binding. Compared with ipamorelin, CJC-1295 works on the GHRH receptor rather than the ghrelin receptor, so stacking is used to stimulate dual pathways, but synergy evidence is mostly mechanistic/preclinical rather than robust human outcomes data. Compared with tesamorelin, CJC-1295 has less clinical-outcomes evidence and no approved indication.

There is no established approved indication for otherwise healthy women, but the mechanism is not sex-restricted; older studies of GHRH analogs and GH-axis therapies included both sexes in some contexts, while specific CJC-1295 data remain limited (review/human context). Avoid use during pregnancy or breastfeeding because there are no pregnancy safety data in the corpus and the GH/IGF-1 axis is biologically active in fetal growth regulation (evidence gap/practitioner consensus). Avoid use with active cancer, prior GH-sensitive tumors, unexplained elevated IGF-1, or uncontrolled diabetes because GH/IGF-1 signaling can support cell proliferation and worsen glycemic control (mechanistic/review).

The corpus supports that CJC-1295 is an injectable peptide commonly sold outside regulated channels, and impurity/quality issues are a real concern for gray-market peptide products (review). Practical handling is product-dependent: lyophilized vials are commonly kept refrigerated after reconstitution, protected from heat/light, and transported cold when possible (community protocol). For travel, the main issue is lawful possession and maintaining cold-chain stability rather than frequent dosing, since DAC formulations are typically injected only weekly or less often (community protocol).